Impax Laboratories, Inc. (IPXL) Analysts See $0.12 EPS; Bay Bancorp (BYBK) Has 1.36 Sentiment

Bay Bancorp, Inc. operates as a bank holding firm for Bay Bank, FSB that provides banking services and products to small and medium-sized commercial and retail businesses, business professionals, and individual clients in the central Maryland region. The company has market cap of $139.33 million. The Company’s deposit products include demand, money market, and savings accounts, as well as time deposits; and certificate of deposit registry service and insured cash sweep deposits. It has a 28.89 P/E ratio. The companyÂ’s loan portfolio comprises commercial loans, such as lines of credit, revolving credit facilities, accounts receivable and inventory financing, term loans, equipment loans, small business administration loans, stand-by letters of credit, and unsecured loans; commercial and residential real estate loans; loans for land acquisition, land development, and/or construction of residential or commercial structures; home equity line of credit; and consumer and other loans, such as installment loans, personal lines of credit, and automobile loans.

Analysts expect Impax Laboratories, Inc. (NASDAQ:IPXL) to report $0.12 EPS on March, 1 before the open.They anticipate $0.04 EPS change or 25.00% from last quarter’s $0.16 EPS. IPXL’s profit would be $8.62M giving it 42.92 P/E if the $0.12 EPS is correct. After having $0.23 EPS previously, Impax Laboratories, Inc.’s analysts see -47.83% EPS growth. The stock decreased 1.67% or $0.35 during the last trading session, reaching $20.6. About 978,306 shares traded or 2.55% up from the average. Impax Laboratories, Inc. (NASDAQ:IPXL) has declined 49.01% since February 28, 2017 and is downtrending. It has underperformed by 65.71% the S&P500.

Among 21 analysts covering Impax Laboratories Inc. (NASDAQ:IPXL), 6 have Buy rating, 2 Sell and 13 Hold. Therefore 29% are positive. Impax Laboratories Inc. had 47 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Friday, June 23 by BMO Capital Markets. The firm earned “Neutral” rating on Tuesday, September 29 by Nomura. The company was maintained on Wednesday, September 13 by Canaccord Genuity. Northland Capital upgraded the stock to “Outperform” rating in Monday, August 15 report. On Thursday, November 10 the stock rating was maintained by RBC Capital Markets with “Sector Perform”. The firm has “Market Perform” rating given on Tuesday, August 11 by Leerink Swann. The stock of Impax Laboratories, Inc. (NASDAQ:IPXL) earned “Sell” rating by Goldman Sachs on Monday, June 6. Guggenheim initiated Impax Laboratories, Inc. (NASDAQ:IPXL) on Tuesday, December 12 with “Hold” rating. The firm has “Hold” rating by Deutsche Bank given on Wednesday, August 10. Canaccord Genuity initiated it with “Hold” rating and $1900 target in Monday, July 31 report.

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, makes, and markets bioequivalent pharmaceutical products. The company has market cap of $1.48 billion. It operates in two divisions, Impax Generics and Impax Specialty Pharma. It currently has negative earnings. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance agreements; generic pharmaceutical over-the-counter and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance agreements.

Investors sentiment increased to 1.75 in 2017 Q3. Its up 0.85, from 0.9 in 2017Q2. It is positive, as 14 investors sold Impax Laboratories, Inc. shares while 39 reduced holdings. 39 funds opened positions while 54 raised stakes. 65.84 million shares or 4.79% more from 62.83 million shares in 2017Q2 were reported. Principal stated it has 0.01% of its portfolio in Impax Laboratories, Inc. (NASDAQ:IPXL). Manufacturers Life The reported 56,027 shares. Dupont Management reported 0.03% stake. The New Jersey-based Prudential has invested 0% in Impax Laboratories, Inc. (NASDAQ:IPXL). California Public Employees Retirement holds 0% or 117,000 shares. Pointstate Cap Limited Partnership holds 73,100 shares. Mason Street Advisors Ltd Liability Company accumulated 0.01% or 18,821 shares. Icon Advisers Co owns 16,255 shares or 0.02% of their US portfolio. Amalgamated Financial Bank owns 9,903 shares. Deutsche National Bank & Trust Ag has invested 0% in Impax Laboratories, Inc. (NASDAQ:IPXL). Parametric Port Associates Limited accumulated 226,168 shares. 64,027 are held by Martingale Asset Mgmt Ltd Partnership. Congress Asset Mngmt Ma invested in 0.06% or 199,831 shares. Verition Fund Mngmt Limited Co has 0.03% invested in Impax Laboratories, Inc. (NASDAQ:IPXL). Pacad Inv Ltd has 21,100 shares for 0.09% of their portfolio.

The post Impax Laboratories, Inc. (IPXL) Analysts See $0.12 EPS; Bay Bancorp (BYBK) Has 1.36 Sentiment appeared first on Stock Market News | HillCountryTimes | Get it Today.

from
https://www.hillcountrytimes.com/2018/02/28/impax-laboratories-inc-ipxl-analysts-see-0-12-eps-bay-bancorp-bybk-has-1-36-sentiment/